NASDAQ$VERV
Verve Therapeutics Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Verve Therapeutics reported its financial results for the second quarter of 2022 and provided corporate updates.
Verve Therapeutics reported a net loss of $40.9 million for the second quarter of 2022. The company's cash, cash equivalents, and marketable securities totaled $293.6 million as of June 30, 2022, which, combined with proceeds from the Vertex collaboration and follow-on offering, is expected to fund operations into the second half of 2025. Patient dosing commenced for VERVE-101, and a lead development candidate, VERVE-201, was nominated.
- Patient dosing is underway with VERVE-101 for Heterozygous Familial Hypercholesterolemia.
- Regulatory clearances in the United Kingdom and United States are anticipated in the second half of 2022.
- Preclinical data supporting nomination of ANGPTL3 development candidate, VERVE-201, will be presented at the European Society of Cardiology 2022 Congress.
- A research collaboration with Vertex and an amendment to Beam License Agreement expanded the pipeline by adding two additional targets.
Headline financials
Revenue & EPS history
Verve Therapeutics · Revenue · Quarterly
$33M
Revenue by segment
Verve Therapeutics · $3.12M total across 1 segment · Q3 2023
- Collaboration Revenue$3.12M—100.0%
Forward guidance
Verve Therapeutics expects that its cash, cash equivalents, and marketable securities as of June 30, 2022, combined with proceeds from the Vertex collaboration and follow-on offering, will be sufficient to fund its operating plan into the second half of 2025.
Tailwinds
- Initiated patient dosing in the heart-1 clinical trial of VERVE-101.
- Anticipates interim clinical data from the heart-1 clinical trial in 2023.
- Expects regulatory clearance for VERVE-101 in the United Kingdom and the United States in the second half of 2022.
- Plans to present preclinical data for VERVE-201 at the ESC 2022 Congress.
- Expects to begin IND-enabling studies for VERVE-201 in the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2022
-1.0%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-3.8%
Avg return
30 days after
47%
8 / 17 earnings
Positive
+24.4%
Q4 2023
Best reaction
-34.2%
Q3 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | +3.4% | +5.0% | +48.1% | |
| Q4 2025 | -1.7% | -2.9% | -16.3% | |
| Q3 2024 | +6.0% | +4.5% | +1.0% | |
| Q2 2024 | -12.1% | -20.8% | -1.6% | |
| Q1 2024 | +3.2% | +0.8% | -15.6% | |
| Q4 2023 | +24.4% | +12.7% | -8.2% | |
| Q3 2023 | +11.8% | +4.8% | -13.8% | |
| Q2 2023 | +2.6% | -9.9% | -28.0% | |
| Q1 2023 | -5.2% | -4.5% | -2.6% | |
| Q4 2022 | +7.0% | +3.0% | -20.8% | |
| Q3 2022 | -34.2% | -13.7% | -31.5% | |
| Q2 2022 | +17.5% | +31.2% | +47.0% | |
| Q1 2022 | -4.4% | +12.8% | +15.2% | |
| Q4 2021 | -20.1% | -4.3% | -19.7% | |
| Q3 2021 | -2.7% | -7.8% | -34.7% | |
| Q4 2020 | -1.4% | +5.5% | +7.5% | |
| Q2 2021 | -10.7% | -11.9% | +10.1% | |
| Q1 2021 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro